iBio is an innovator biologics company developing therapeutics and vaccines for the betterment of human and animal health with pipeline candidates targeting systemic sceleroderma (IBIO-100), COVID-19 (IBIO-200 and IBIO-201), and classical swine fever (IBIO-400). iBio’s subsidiary, iBio CDMO is a global leader in plant-based manufacturing. It’s FastPharming® and FastGlycaneering™ platforms provide contract development and manufacturing services via its 130,000 square foot facility in Bryan, Texas. The speed and scalability of FastPharming make it an ideal choice for other innovator companies who want to rapidly produce biologics.
September 9, 2020
iBio to Advance COVID-19 LicKM-Subunit Vaccine Candidate, IBIO-201
– IBIO-201 Produced Anti-Spike Neutralizing Antibodies in Pre-Clinical Studies – – iBio Plans to ...
August 10, 2020
iBio Provides Update on IBIO-201 COVID-19 Vaccine Program
IBIO-201 Demonstrates Ability to Elicit anti-SARS-CoV-2 Immune Response in Preclinical Studies NEW ...
June 24, 2020
TEXAS A&M TESTS COVID-19 VACCINE CANDIDATES FOR IBIO, INC.
by tamus | Jun 24, 2020 | System News Chancellor Sharp praises partnership between ...